| Systemic haemodynamic and humoral changes during urapidil treatment in hypertensive patients. | |
| | |
MedLine Citation:
|
PMID: 2906697 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
Urapidil, a new antihypertensive agent exerting a peripheral alpha 1-postsynaptic blocking action and an additional action at the central level, has some characteristics which may correct the underlying pathophysiological abnormalities found in the great majority of hypertensive patients. When administered acutely and chronically, urapidil significantly lowers blood pressure in hypertensive patients by reducing total peripheral resistance, while cardiac output is unchanged or only slightly elevated. The blood pressure reduction can cause a decrease in cardiac mass in patients with left ventricular hypertrophy. Urapidil has been successfully administered also in patients with congestive heart failure and in hypertensive crises during or following surgical procedures; in all these conditions urapidil lowers total peripheral resistance, but blood pressure is lowered only in patients with hypertensive crises and no clinically relevant reduction in blood pressure is found in patients with congestive heart failure. The acute administration of urapidil has shown a trend towards a rise in plasma renin activity, in plasma aldosterone and in plasma catecholamines; on the whole, however, the activation of these systems has been mild. |
| | |
Authors:
|
G Leonetti; L Terzoli; A Zanchetti |
Related Documents
:
|
9443767 - Association between increased plasma levels of aldosterone and decreased systemic arter... 20083287 - Clinical outcome after laparoscopic adrenalectomy for primary hyperaldosteronism: the r... 11560127 - Early rise in blood pressure following administration of adrenocorticotropic hormone-[1... 18268147 - Association of leukocyte telomere length with circulating biomarkers of the renin-angio... 10926177 - Theoretical basis and clinical evidence for differential effects of angiotensin-convert... 18549907 - Warfarin-induced bleeding complications - clinical presentation and therapeutic options. |
Publication Detail:
|
Type: Clinical Trial; Journal Article; Review |
Journal Detail:
|
Title: Journal of hypertension. Supplement : official journal of the International Society of Hypertension Volume: 6 ISSN: 0952-1178 ISO Abbreviation: J Hypertens Suppl Publication Date: 1988 Dec |
Date Detail:
|
Created Date: 1989-04-12 Completed Date: 1989-04-12 Revised Date: 2007-11-15 |
Medline Journal Info:
|
Nlm Unique ID: 8501422 Medline TA: J Hypertens Suppl Country: ENGLAND |
Other Details:
|
Languages: eng Pagination: S25-9 Citation Subset: IM |
Affiliation:
|
Istituto di Clinica Medica Generale e Terapia Medica, University of Milan, Italy. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Adrenergic alpha-Antagonists Antihypertensive Agents / therapeutic use* Clinical Trials as Topic Hemodynamics / drug effects* Humans Hypertension / drug therapy* Piperazines / therapeutic use* |
| Chemical | |
Reg. No./Substance:
|
0/Adrenergic alpha-Antagonists; 0/Antihypertensive Agents; 0/Piperazines; 34661-75-1/urapidil |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Alpha-adrenoceptors and the kidney.
Next Document: Basic pharmacology of alpha-adrenoceptor antagonists and hybrid drugs.